Van Hulzen Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.11M | Buy |
39,543
+3,552
| +10% | +$94.6K | 0.08% | 151 |
|
|
2025
Q4 | $896K | Buy |
35,991
+11,382
| +46% | +$287K | 0.07% | 173 |
|
|
2025
Q3 | $627K | Buy |
24,609
+7
| +0% | +$173 | 0.05% | 207 |
|
|
2025
Q2 | $596K | Buy |
24,602
+60
| +0.2% | +$1.4K | 0.05% | 200 |
|
|
2025
Q1 | $622K | Buy |
24,542
+830
| +4% | +$21.7K | 0.06% | 190 |
|
|
2024
Q4 | $629K | Sell |
23,712
-9,235
| -28% | -$250K | 0.05% | 205 |
|
|
2024
Q3 | $953K | Buy |
32,947
+4,741
| +17% | +$138K | 0.07% | 163 |
|
|
2024
Q2 | $789K | Buy |
28,206
+3,033
| +12% | +$83.5K | 0.05% | 171 |
|
|
2024
Q1 | $699K | Sell |
25,173
-1,445
| -5% | -$40.1K | 0.05% | 195 |
|
|
2023
Q4 | $766K | Sell |
26,618
-174
| -0.6% | -$5.26K | 0.05% | 187 |
|
|
2023
Q3 | $889K | Sell |
26,792
-33,342
| -55% | -$1.18M | 0.07% | 165 |
|
|
2023
Q2 | $2.21M | Buy |
60,134
+7,903
| +15% | +$308K | 0.19% | 86 |
|
|
2023
Q1 | $2.13M | Buy |
52,231
+28,050
| +116% | +$1.21M | 0.2% | 82 |
|
|
2022
Q4 | $1.24M | Buy |
24,181
+1,126
| +5% | +$54K | 0.14% | 111 |
|
|
2022
Q3 | $1.01M | Sell |
23,055
-1,007
| -4% | -$48.9K | 0.12% | 116 |
|
|
2022
Q2 | $1.26M | Buy |
24,062
+605
| +3% | +$30.8K | 0.15% | 107 |
|
|
2022
Q1 | $1.21M | Sell |
23,457
-3,490
| -13% | -$181K | 0.13% | 103 |
|
|
2021
Q4 | $1.59M | Sell |
26,947
-2,204
| -8% | -$109K | 0.17% | 93 |
|
|
2021
Q3 | $1.25M | Buy |
29,151
+201
| +0.7% | +$8.9K | 0.19% | 85 |
|
|
2021
Q2 | $1.13M | Buy |
28,950
+5,275
| +22% | +$205K | 0.17% | 84 |
|
|
2021
Q1 | $858K | Sell |
23,675
-36,509
| -61% | -$1.3M | 0.14% | 95 |
|
|
2020
Q4 | $2.21M | Sell |
60,184
-191,472
| -76% | -$7.02M | 0.34% | 66 |
|
|
2020
Q3 | $8.76M | Sell |
251,656
-25,851
| -9% | -$906K | 1.32% | 24 |
|
|
2020
Q2 | $8.61M | Buy |
277,507
+25,814
| +10% | +$877K | 1.29% | 22 |
|
|
2020
Q1 | $7.79M | Buy |
251,693
+15,478
| +7% | +$527K | 1.68% | 17 |
|
|
2019
Q4 | $8.78M | Buy |
236,215
+31,600
| +15% | +$1.13M | 1.7% | 14 |
|
|
2019
Q3 | $6.97M | Buy |
204,615
+13,368
| +7% | +$486K | 1.47% | 22 |
|
|
2019
Q2 | $7.86M | Buy |
191,247
+24,541
| +15% | +$974K | 1.72% | 19 |
|
|
2019
Q1 | $6.72M | Buy |
166,706
+145,222
| +676% | +$5.82M | 1.81% | 17 |
|
|
2018
Q4 | $890K | Sell |
21,484
-102
| -0.5% | -$4.23K | 0.26% | 73 |
|
|
2018
Q3 | $903K | Sell |
21,586
-120,835
| -85% | -$4.65M | 0.24% | 76 |
|
|
2018
Q2 | $4.9M | Buy |
142,421
+10,985
| +8% | +$375K | 1.45% | 21 |
|
|
2018
Q1 | $4.43M | Buy |
131,436
+35,945
| +38% | +$1.24M | 1.36% | 22 |
|
|
2017
Q4 | $3.28M | Sell |
95,491
-659
| -0.7% | -$22.5K | 1% | 35 |
|
|
2017
Q3 | $3.26M | Buy |
96,150
+5,328
| +6% | +$171K | 1.1% | 31 |
|
|
2017
Q2 | $2.89M | Buy |
90,822
+3,900
| +4% | +$123K | 1.15% | 37 |
|
|
2017
Q1 | $2.82M | Sell |
86,922
-6,276
| -7% | -$198K | 1.29% | 27 |
|
|
2016
Q4 | $2.87M | Buy |
93,198
+3,171
| +4% | +$96.8K | 1.33% | 28 |
|
|
2016
Q3 | $2.89M | Buy |
90,027
+57,428
| +176% | +$1.92M | 1.57% | 21 |
|
|
2016
Q2 | $1.09M | Buy |
32,599
+16,126
| +98% | +$515K | 0.62% | 50 |
|
|
2016
Q1 | $463K | Sell |
16,473
-89
| -0.5% | -$2.54K | 0.26% | 77 |
|
|
2015
Q4 | $507K | Buy |
16,562
+1,581
| +11% | +$49.7K | 0.32% | 69 |
|
|
2015
Q3 | $446K | Buy |
14,981
+380
| +3% | +$12.2K | 0.29% | 72 |
|
|
2015
Q2 | $464K | Sell |
14,601
-34,761
| -70% | -$1.13M | 0.25% | 84 |
|
|
2015
Q1 | $1.63M | Buy |
49,362
+20,986
| +74% | +$667K | 1% | 36 |
|
|
2014
Q4 | $839K | Buy |
28,376
+11,290
| +66% | +$324K | 0.58% | 46 |
|
|
2014
Q3 | $479K | Buy |
17,086
+2,784
| +19% | +$78.1K | 0.49% | 54 |
|
|
2014
Q2 | $403K | Buy |
14,302
+423
| +3% | +$12.1K | 0.35% | 60 |
|
|
2014
Q1 | $423K | Sell |
13,879
-131
| -0.9% | -$3.91K | 0.43% | 58 |
|
|
2013
Q4 | $407K | Buy |
+14,010
| New | +$408K | 0.35% | 69 |
|
Other funds holding PFE
VCM
VPM
Van Hulzen Asset Management's PFE Position: Q1 2026 in Review
Van Hulzen Asset Management increased its Pfizer (PFE) stake by 9.9% in Q1 2026, buying an estimated $94.6K and bringing the position to 39,543 shares worth $1.11M. The position accounts for 0.08% of the portfolio, ranked #151.
Van Hulzen Asset Management first reported a position in PFE in Q4 2013 and has held it in 50 quarters since. The position peaked at $8.78M in Q4 2019. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Van Hulzen Asset Management held 39,543 shares of Pfizer worth $1.11M as of Q1 2026.
- Van Hulzen Asset Management bought 3,552 Pfizer shares in Q1 2026, an estimated $94.6K.
- Pfizer made up 0.08% of Van Hulzen Asset Management's portfolio in Q1 2026, its #151 holding.
- Van Hulzen Asset Management first reported a position in Pfizer in Q4 2013 and has held it in 50 quarters since.
- Van Hulzen Asset Management's Pfizer position peaked at $8.78M in Q4 2019.
- 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Van Hulzen Asset Management's 13F filing for Q1 2026, filed 14 May 2026.